Primary Cells

T5539 Normal Human Primary Plateable Hepatocytes

T5539 Normal Human Primary Plateable Hepatocytes by ABM — non-characterized plateable human hepatocytes; 5×10⁵ cells/1.0 ml, BSL-II. Two-phase protocol: plate with TM088 → switch to TM089 once attached. PriCoat™ ECM T25 Flasks (G999) required. MTA required.

T5541 Normal Human Primary Plateable Hepatocytes

T5541 Normal Human Primary Plateable Hepatocytes by ABM — normal human hepatocytes optimized for attachment post-thaw, 5×10⁵ cells/1.0 ml, BSL-II. Two-phase media: plate with TM088 → switch to TM089 once attached. PriCoat™ ECM T25 Flasks (G999) required. MTA required.

T5546 Normal Human Primary Hepatic Stellate Cells

T5546 Normal Human Primary Hepatic Stellate Cells by ABM — cryopreserved normal liver HSCs, adherent polygonal, 5×10⁵ cells/1.0 ml, BSL-II. Seeding 4,000 cells/cm²; subculture at 90%; media change every other day post-24h. Sinusoidal Endothelial Cell Growth Medium (TM086) and G999 ECM flasks required. MTA required.

T5549 Normal Human Primary Hepatic Kupffer Cells

T5549 Normal Human Primary Hepatic Kupffer Cells by ABM — resident liver macrophages expressing CD68, TNF-α, IL-6, CD34, F4/80; 5×10⁵ cells/1.0 ml, BSL-II. Seeding 13,000–15,000 cells/cm²; 100×g centrifuge; 48h undisturbed recovery; max 7-day culture; no subculture. G999 ECM flasks and PriGrow TM5549 required. MTA required.

T5555 Normal Human Primary Intrahepatic Biliary Epithelial Cells (Cholangiocytes)

T5555 Normal Human Primary Intrahepatic Biliary Epithelial Cells (Cholangiocytes) by ABM — normal bile duct cholangiocytes; 5×10⁵ cells/1.0 ml, BSL-II. Seeding 5,000 cells/cm²; 300×g centrifuge on thaw; undisturbed 12h; media at 24h then every other day. TM087 Cholangiocyte Medium + G999 ECM flasks required. MTA required.

T5558 Normal Human Primary Sinusoidal Endothelial Cells

T5558 Normal Human Primary Sinusoidal Endothelial Cells by ABM — normal liver sinusoidal endothelium, endothelial-like, 5×10⁵ cells/1.0 ml, BSL-II. Sinusoidal Endothelial Cell Growth Medium (TM086) required; G299/G422 flasks. For liver LSEC biology and NASH research. MTA required.

T5995 Normal Human Primary Sinusoidal Endothelial Cells

T5996 Enhanced Primary Human Hepatocytes - 5 million

T5996 Enhanced Primary Human Hepatocytes by ABM — expanded primary hepatocytes retaining CYP activity; 5×10⁶ cells/1.0 ml, BSL-II. Seeding 10,000 cells/cm²; 90×g only centrifuge; max 18-day culture; media every 2–3 days. Hepatocyte Thawing Medium (TM102) + Growth Kit (TM103) required. MTA required.

T5997 Enhanced Primary Human Liver Sinusoidal Endothelial Cells

T5997 Enhanced Primary Human Liver Sinusoidal Endothelial Cells by ABM — expanded LSECs; MMR+/CD31+; 5×10⁵ cells/1.0 ml, BSL-II. Seeding 10,000 cells/cm²; max 1–2 passages; subculture at 70–80%. TrypLE Express (PBS wash first); 280×g; TM111 thaw → TM112 growth media; G422 coating. MTA required.

<h2>What Are RNA-Modifying Enzymes?</h2>
&nbsp;
RNA-modifying enzymes act on RNA substrates to add, remove, or chemically alter nucleotides and terminal structures. Key enzymes in this category include poly(A) polymerase (PAP), which adds untemplated adenosine residues to RNA 3' ends; T4 RNA Ligase 1, which joins single-stranded RNA; T4 RNA Ligase 2, which joins nicked duplex RNA; vaccinia virus capping enzyme (VCE), which adds a 7-methylguanosine cap to the 5' end of mRNA; 2'-O-methyltransferase, which modifies the cap to generate a Cap 1 structure; and RNA methyltransferases such as METTL3/METTL14 complex used in m6A epitranscriptomics research. These enzymes are foundational tools in the fast-growing field of mRNA-based therapeutics and diagnostics, as well as long-read sequencing library construction. Select RNA-modifying enzymes based on RNA substrate type (single-stranded, duplex, capped), required end structure, and downstream application (therapeutic vs. research grade).
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" aria-level="1">
T7 RNA Polymerase: The rapid powerhouse of in vitro transcription, ideal for producing large quantities of RNA from DNA templates for probes or functional mRNA research.
</li>
<li dir="ltr" aria-level="1">
Poly(A) Polymerase (Yeast &amp; E. coli): The definitive stabilizing agent, attaching adenosine tails to the 3' terminus of transcripts to enhance their longevity and translation efficacy&mdash;a crucial element for precise library preparation.
</li>
</ul>
&nbsp;
<h2>How to Choose RNA-Modifying Enzymes</h2>
&nbsp;
Poly(A) tailing vs. RNA ligation.
Poly(A) polymerase is used when a 3'-poly(A) tail is needed for mRNA stabilization, translation enhancement, or as a primer binding site for oligo(dT)-based cDNA synthesis. T4 RNA Ligase 1 (single-strand-specific) is used for adaptor ligation to RNA 3' ends in small RNA sequencing library preparation. T4 RNA Ligase 2 truncated version (paired with a splint oligonucleotide) gives higher efficiency adaptor ligation with less secondary structure bias.
mRNA capping
5'-cap structures protect mRNA from exonucleolytic degradation and are recognized by eIF4E for ribosome recruitment. Vaccinia Capping Enzyme adds a Cap 0 structure; co-treatment with 2'-O-methyltransferase (mRNA Cap 2'-O-Methyltransferase) converts Cap 0 to Cap 1, which reduces innate immune recognition -- critical for therapeutic mRNA applications. Co-transcriptional capping with CleanCap analogs avoids the separate capping step.
Epitranscriptomics
m6A RNA methyltransferases (METTL3, METTL14, WTAP complex) and demethylases (FTO, ALKBH5) are used to add or remove N6-methyladenosine modifications in cellular RNA for functional studies. These enzymes require S-adenosylmethionine (SAM) as a methyl donor and are supplied at a microgram scale for biochemical assays.
RNase inhibitor pairing
All RNA-modifying enzyme reactions require an RNase-free environment. Include RNase inhibitor protein at 0.5-2 U per microliter in reactions without heat-inactivation capability. Use DEPC-treated water and certified RNase-free tubes and tips for all RNA work.
Application scale
Research-grade RNA-modifying enzymes are available in standard unit sizes for individual experiments. For manufacturing-adjacent workflows (large-scale IVT for mRNA vaccines or CAR-T cell therapy applications), contact MBP for volume pricing and GMP-compatible sourcing options.
&nbsp;
<h2>Specifications Context</h2>
&nbsp;
Poly(A) polymerase activity is measured as the amount of enzyme incorporating 1 nmol of AMP into acid-precipitable RNA in 30 minutes at 37 degrees C. Typical poly(A) tail lengths of 100-250 nucleotides are generated in 10-20 minute reactions at 37 degrees C with 1 mM ATP and 2-5 U of enzyme per microgram of RNA. Vaccinia Capping Enzyme reaction efficiency exceeds 95% for IVT transcripts of 500-5000 nt when used at recommended ratios; verify by LC-MS or HPLC analysis for therapeutic applications. Co-transcriptional Cap 1 capping using modified trinucleotide cap analogs is increasingly adopted in mRNA manufacturing to eliminate separate enzymatic capping steps.&nbsp;
&nbsp;
Prepared to customize your transcripts? <a href="https://mbpinc.net/contact-us">Contact the MBP team</a> today for a personalized quote on our RNA-modifying tools.

RNA-modifying enzymes

MSDS

T7 RNA Polymerase

Unit Quantity

Concentration

Components

Storage Buffer

Storage Condition

Note

Shipping Condition

Tumor cells

Thawing Protocol

Cell Line Catalog (Volume 2)

T8000 EACH-1 Cells

EACH-1 Cells (T8000) by MBP are novel extra-axial chordoma tumor cells, tumorigenic and able to form colonies on soft agar. Used for research on the rare low-grade malignant tumor parachordoma. Human (H. sapiens), bone tissue, adherent polygonal. BSL II. 1&times;106 cells / 1.0 mL, frozen. MTA required.

T8001 IU-TAB-1 Cells

T8001 IU-TAB-1 Cells by MBP. 1&times;106 cells / 1.0 mL, frozen. Contact MBP for full specifications and pricing.